Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Free Cash Flow (2021 - 2026)

MoonLake Immunotherapeutics' Free Cash Flow history spans 6 years, with the latest figure at -$66.3 million for Q1 2026.

  • Quarterly Free Cash Flow fell 73.64% to -$66.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$224.2 million through Mar 2026, down 59.97% year-over-year, with the annual reading at -$196.0 million for FY2025, 67.4% down from the prior year.
  • Free Cash Flow came in at -$66.3 million for Q1 2026, down from -$58.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$9.0 million in Q1 2023 to a low of -$66.3 million in Q1 2026.
  • The 5-year median for Free Cash Flow is -$20.8 million (2022), against an average of -$28.1 million.
  • The largest YoY upside for Free Cash Flow was 67.08% in 2022 against a maximum downside of 13074.98% in 2022.
  • MoonLake Immunotherapeutics' Free Cash Flow stood at -$11.6 million in 2022, then dropped by 8.9% to -$12.6 million in 2023, then tumbled by 285.24% to -$48.6 million in 2024, then dropped by 20.85% to -$58.8 million in 2025, then dropped by 12.74% to -$66.3 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Free Cash Flow are -$66.3 million (Q1 2026), -$58.8 million (Q4 2025), and -$44.5 million (Q3 2025).